CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov. 1, 2017--
Pharmaceuticals, Inc. (NASDAQ: IRWD) will present a corporate update
at the Credit Suisse 26th Annual Healthcare Conference on
Wednesday, November 8th, 2017 at 10:25 a.m. Mountain Time/
12:25 p.m. Eastern Time at The Phoenician in Scottsdale, Arizona.
A live webcast of Ironwood’s presentation will be accessible through the
Investors section of the company’s website at www.ironwoodpharma.com.
To access the webcast, please log on to the Ironwood website
approximately 15 minutes prior to the start time to ensure adequate time
for any software downloads that may be required. A replay of the webcast
will be available on Ironwood’s website for 14 days following the
About Ironwood Pharmaceuticals
Ironwood Pharmaceuticals (NASDAQ: IRWD) is a commercial biotechnology
company focused on creating medicines that make a difference for
patients, building value for our fellow shareholders, and empowering our
passionate team. We are commercializing two innovative primary care
products: linaclotide, the U.S. branded prescription market leader for
adults with irritable bowel syndrome with constipation (IBS‐C) or
chronic idiopathic constipation (CIC), and lesinurad, which is approved
for the treatment of hyperuricemia associated with gout in patients who
have not achieved target serum uric acid (sUA) levels with a medically
appropriate daily dose of a xanthine oxidase inhibitor (XOI) alone. We
are also advancing a pipeline of internally and externally generated
innovative product candidates in areas of significant unmet need,
including uncontrolled gastroesophageal reflux disease and vascular and
fibrotic diseases. Ironwood was founded in 1998 and is headquartered in
Cambridge, Mass. For more information, please visit www.ironwoodpharma.com
information that may be important to investors will be routinely posted
in both these locations.
View source version on businesswire.com: http://www.businesswire.com/news/home/20171101006444/en/
Source: Ironwood Pharmaceuticals, Inc.
Ironwood Pharmaceuticals, Inc.
Meredith Kaya, 617-374-5082
Director, Investor Relations and Corporate Communications